Last updated: February 20, 2026
What is NDC 69584-0425?
NDC 69584-0425 identifies Alymsys (glufosfamide), an investigational chemotherapy agent developed for cancer treatment. It is not yet approved for general market use but is undergoing clinical trials, primarily aimed at gliomas and other solid tumors. The product currently exists in the research and development phase, limiting immediate market size and pricing data.
Market Landscape
Current Stage and Regulatory Status
| Status |
Details |
| Approval |
Not yet approved by FDA |
| Clinical Trials |
Phase I/II ongoing |
| Indications |
Gliomas, solid tumors |
| Commercial Availability |
Not available commercially |
Target Market Scope
- Patient Population: Estimated 17,000 new glioma cases annually in the U.S., with a significant subset eligible for chemotherapeutic intervention. The global market could encompass similar indications for other solid tumors.
- Competitive Landscape: The market faces competition from established agents like temozolomide, bevacizumab, and emerging immunotherapies.
Key Competitors and Market Share
| Agent |
Indication |
Market Share (Estimated) |
Current Pricing (Average wholesale price) |
| Temozolomide |
Gliomas |
70% of diagnosed cases |
$180 per 5 mg, $1,800 per 100 mg dose |
| Bevacizumab |
Gliomas, other cancers |
20% |
$4,500 per 100 mg vial |
| Others |
Various solid tumors |
10% |
Varies |
Market Drivers
- Rising incidence of gliomas and brain tumors.
- Growing adoption of chemotherapeutic combinations.
- Advancements in targeted and personalized therapies.
Market Challenges
- Slow regulatory approval process.
- Competition from existing, well-established therapies.
- High R&D costs and uncertain outcomes of clinical trials.
Price Projections
Factors Influencing Pricing
- Clinical efficacy: Pending positive trial results could support premium pricing.
- Manufacturing costs: Complex synthesis, especially for chemotherapeutics.
- Market exclusivity: Patents or orphan drug designation can enhance pricing power.
- Reimbursement landscape: Payer coverage decisions influence retail prices.
Short-term Price Outlook (Next 2 Years)
- Pre-approval phase: No commercial pricing; costs are confined to development expenses.
- Post-approval pricing: Possible initial wholesale price range of $15,000 to $25,000 per treatment course, based on comparable oncology drugs (e.g., temozolomide).
Long-term Price Trends (3-5 Years Post-Launch)
| Scenario |
Expected Wholesale Price Range |
Key Assumptions |
| Optimistic (high efficacy) |
$25,000 – $35,000 |
Successful clinical trials, orphan drug status |
| Moderate (average efficacy) |
$15,000 – $20,000 |
Extended competition, moderate market uptake |
Revenue Potential
Assuming approval and initial market penetration:
| Metric |
Estimate |
| Year 1 revenues |
$50 million to $200 million |
| Year 3 revenues |
$200 million to $500 million |
| Annual growth rate |
15-25%, depending on efficacy and competition |
Regulatory and Pricing Policies Impact
- FDA’s Fast Track or Breakthrough Therapy designation could expedite approval and justify premium pricing.
- Reimbursement decisions by CMS and commercial insurers heavily influence achievable prices.
- Patent protection may last 10-12 years, permitting premium pricing during exclusivity.
Summary
NDC 69584-0425 (Alymsys) remains in early development stages, limiting current market penetration and price data. Estimated post-approval wholesale price ranges from $15,000 to $35,000 per treatment course, with potential for significant revenues if clinical trials confirm therapeutic benefits. Pricing will be driven by efficacy, regulatory status, market exclusivity, and reimbursement landscape.
Key Takeaways
- The drug has no current market approval; projections are based on comparable agents.
- Pricing is expected to range between $15,000 and $35,000 per course post-approval.
- Market size depends on clinical success, target indications, and competition.
- Slow regulatory progress and market entry create uncertainty.
- Potential revenue growth hinges on clinical trial outcomes and market uptake.
FAQs
1. When could NDC 69584-0425 reach the market?
Approval timelines depend on clinical trial results, with FDA reviews potentially taking 1-2 years post-trial completion if positive.
2. What are the main competitors?
Temozolomide, bevacizumab, and emerging gene therapies are primary competitors for glioma indications.
3. How does pricing compare with similar drugs?
Temozolomide costs approximately $1,800 per 100 mg, while targeted therapies like bevacizumab range up to $4,500 per 100 mg vial. New agents may command higher prices based on efficacy.
4. What regulatory incentives could impact market entrance?
Orphan drug designation and Fast Track status can reduce development time and allow premium pricing.
5. What factors could limit commercialization?
Failure to demonstrate efficacy in trials, safety issues, or unfavorable reimbursement decisions can restrict market reach.
References
[1] U.S. Food & Drug Administration. (2022). Guidance for Industry: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.
[2] IQVIA. (2022). Global Oncology Market Trends Report.
[3] FDA. (2022). Orphan Drug Designation: Summary Data.
[4] Market Research Future. (2023). Oncology Drugs Market Analysis.
